Kymera Therapeutics, Inc. (KYMR) stock forecast and price target
Price $127.57 · data as of November 13, 2026
12-month price target
Average target$145.22
Upside / downside+13.8%
Analysts23
ConsensusStrong buy
Low $116.00Average $145.22High $180.00
Gold marker: average target · white marker: today’s price ($127.57)
Analyst ratings
Strong buy 5Buy 17Hold 2Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.93 | −6.4% | $99M |
| Next fiscal year ends December 31, 2027 | $-5.12 | −30.3% | $42M |
| Next quarter ends December 31, 2026 | $-1.29 | −31.3% | $62500 |
| Quarter after ends March 31, 2027 | $-1.35 | −90.1% | $7M |
Consensus of the analysts covering Kymera Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 8 lowered.
Frequently asked questions
What is the Kymera Therapeutics stock price target?
The average 12-month target from 23 analysts is $145.22, 13.8% above the current price of $127.57 Targets range from $116.00 to $180.00.
Is Kymera Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (5 strong buy, 17 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Kymera Therapeutics expected to earn?
Analysts expect EPS of $-3.93 for the fiscal year ending December 31, 2026 and $-5.12 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.